Identity recordChina-approved medicine and active clinical program
What Mazdutide resolves to
Mazdutide has NMPA approvals in China for chronic weight management and glycemic control in adults with type 2 diabetes. Those China-specific approvals do not establish FDA approval, authorization in another country, or the identity and authority of an online seller.
- Evidence lane
- Clinical pipeline profile
- Current record
- China approvals active; Phase 3 and indication-expansion studies continue
- Checked
- July 22, 2026
IBI362LY3305677GLP-1/glucagon dual agonist
Destination recordCentral and state records must be separated
What India still has to prove
An India-specific guide to using CDSCO approval and quality-alert records before treating a peptide name, clinic claim, imported listing, or laboratory document as verified evidence.
- Comparison mode
- INR / CDSCO approval and alert records
- Price coverage
- No qualified India seller table
- Guide updated
- July 18, 2026